Cargando…
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved...
Autores principales: | Schweighofer, Carmen Diana, Wendtner, Clemens-Martin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895774/ https://www.ncbi.nlm.nih.gov/pubmed/20616957 |
Ejemplares similares
-
Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007) -
Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008) -
Role of rituximab in first-line treatment of chronic lymphocytic leukemia
por: Bryan, Jeffrey, et al.
Publicado: (2011) -
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
por: Karlsson, C, et al.
Publicado: (2011) -
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia
por: Ronchetti, Anne-Marie, et al.
Publicado: (2014)